Redefining Affective Disorders: Relevance for Drug Development
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The evaluation of new drug entities with specific modes of action may be hampered by rigid diagnostic classification systems and patient selection processes that do not focus on the anticipated symptomatic, behavioral, and functional outcomes to be achieved. Patients enrolled in central nervous system (CNS) clinical trials may present with a heterogeneous group of symptoms representing several syndromes or subtypes, subsumed under the same diagnosis in the DSM‐IV classification system. As a result, enrolled patients may not have the valid illness characteristics of interest to the particular study. We propose that clinical drug development needs to focus on the primary nosological entity likely to be affected by a new drug entity's mode of action. Ideally, a valid patient will have the acute primary symptoms that the novel drug is supposed to influence. In this article, we propose operational criteria to delineate a more symptom‐specific and ecologically valid approach to the identification of the valid patient for clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationEstablishment of Diagnostic Validity in Psychiatric Illness: Its Application to Schizophrenia
ROBINS, E., & GUZE, S. B. (1970) · American Journal of Psychiatry · doi:10.1176/ajp.126.7.983 · Cited by 2,243
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177 · cited 1×
“A case illustration follows: A patient is being evaluated for a clinical study of melancholic depression in which the Inventory of Depressive Symptomatology (IDS) 30-item version is employed (Rush et al. 1996) and at least four valid symptoms of melancholic depression are required.”
MethodBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002 · cited 4×
“For example, the recent NIMH-sponsored STAR∗D study demonstrated that only 27.5% of depressed patients treated with a first-line, FDA-approved SSRI-antidepressant (citalopram) achieved remission despite adequate dose and treatment duration (Trivedi et al. 2006a).”
BackgroundInfluentialFava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
FAVA, M., ALPERT, J. E., CARMIN, C. N., WISNIEWSKI, S. R., TRIVEDI, M. H., BIGGS, M. M., SHORES-WILSON, K., MORGAN, D., SCHWARTZ, T., BALASUBRAMANI, G. K., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291704002612 · Cited by 406
“Psychiatric comorbidity”: an artefact of current diagnostic systems?
Maj, M. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.186.3.182 · Cited by 305
Cited by
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525
“Additional inclusion criteria were qualifying valid depressive episodes, as assessed with the SAFER criteria (12) (defined as state versus trait, assessability, face validity, ecological validity, and rule of three Ps—pervasive, persistent, and pathological); inadequate response to at least two antidepressants (with a…”
MethodFava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., Du, Y., Leigh-Pemberton, R., DiPetrillo, L., Silverman, B., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15070921 · Cited by 232
“DSM-IV-TRAxis I Disorders criteria for a diagnosis ofmajor depressive disorder, which was validated using a SAFER interview administered by remote, independent raters (28).”
MethodFava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., Harper, L., Levy, M., Rickels, K., & Pollack, M. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000332050 · Cited by 141
Self-citationRatti, E., Bettica, P., Alexander, R., Archer, G., Carpenter, D., Evoniuk, G., Gomeni, R., Lawson, E., Lopez, M., Millns, H., et al. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113480990 · Cited by 69
“In Study 733 patients proposed for randomization by each site were then interviewed remotely by a clinical expert using the SAFER criteria (Targum et al., 2008) for diagnostic reassessment, confirming the eligibility or excluding the patient according to the study’s psychiatric inclusion and exclusion criteria.”
MethodInfluentialFava, M., Johe, K., Ereshefsky, L., Gertsik, L. G., English, B. A., Bilello, J. A., Thurmond, L. M., Johnstone, J., Dickerson, B. C., Makris, N., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.178 · Cited by 45
Metadata
- Authors
- Targum, S. D., Pollack, M. H., & Fava, M.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2008-03
- Volume
- 14
- Issue
- 1
- Pages
- 2-9
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W2154962555
- Cited by
- 45
- References
- 8
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Redefining Affective Disorders: Relevance for Drug Development. https://app.cochat.ai/papers/10.1111/j.1527-3458.2008.00038.x
- The paper
- Targum, S. D., Pollack, M. H., & Fava, M. (2008). Redefining Affective Disorders: Relevance for Drug Development. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1527-3458.2008.00038.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.